Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib Using 7T MRI in Relapsing or Progressive MS
NCT07222956Phase 2Not yet recruiting
- Start
- Mar 2027
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of remibrutinib in multiple sclerosis (MS). Primary endpoints: Quantitative MRI volumetric measurements at Month 24, Slowly expanding lesions at Month 24 and 8 more. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
remibrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07222956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222956.